Quotient Limited (NASDAQ:QTNT) insider D J. Paul E. Cowan sold 100,000 shares of the business’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $4.64, for a total value of $464,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Quotient Limited (QTNT) traded up 3.88% on Wednesday, reaching $4.55. The company’s stock had a trading volume of 410,025 shares. The stock’s market cap is $65.41 million. The company’s 50 day moving average price is $4.46 and its 200-day moving average price is $5.96. Quotient Limited has a 12-month low of $3.22 and a 12-month high of $8.20.

Quotient Limited (NASDAQ:QTNT) last posted its earnings results on Monday, August 7th. The company reported ($0.55) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.55). The business had revenue of $6.83 million during the quarter, compared to analyst estimates of $5.70 million. Quotient Limited had a negative return on equity of 13,050.41% and a negative net margin of 381.66%. On average, equities analysts expect that Quotient Limited will post ($2.01) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/18/quotient-limited-qtnt-insider-sells-464000-00-in-stock.html.

Several research firms have weighed in on QTNT. ValuEngine raised Quotient Limited from a “strong sell” rating to a “sell” rating in a research report on Friday, June 30th. Zacks Investment Research cut Quotient Limited from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 26th. Finally, BTIG Research reissued a “buy” rating and issued a $12.00 price objective on shares of Quotient Limited in a research report on Thursday, August 31st.

Several hedge funds have recently added to or reduced their stakes in QTNT. New York State Common Retirement Fund purchased a new position in shares of Quotient Limited in the 2nd quarter worth $101,000. Goldman Sachs Group Inc. purchased a new position in shares of Quotient Limited in the 2nd quarter worth $104,000. Nationwide Fund Advisors purchased a new position in shares of Quotient Limited in the 2nd quarter worth $111,000. The Manufacturers Life Insurance Company purchased a new position in shares of Quotient Limited in the 2nd quarter worth $177,000. Finally, Rhumbline Advisers purchased a new position in shares of Quotient Limited in the 2nd quarter worth $201,000. Hedge funds and other institutional investors own 57.71% of the company’s stock.

Quotient Limited Company Profile

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.

Insider Buying and Selling by Quarter for Quotient Limited (NASDAQ:QTNT)

Receive News & Stock Ratings for Quotient Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient Limited and related stocks with our FREE daily email newsletter.